EUVIMEDEUVIMED entdecken
Open Access

Anxiofit‐1 and reduction of subthreshold and mild anxiety: Evaluation of a health claim pursuant to article 14 of regulation (EC) No 1924/2006

EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Dominique Turck, Torsten Bohn, Montaña Cámara, Jacqueline Castenmiller, Stefaan de Henauw, Karen-Ildico Hirsch-Ernst, Angeles Jos, Alexandre Maciuk, Inge Mangelsdorf, Breige McNulty, Androniki Naska und 5 weitere

EFSA Journal · 2026-03 · 24 (3)

DOI: 10.2903/j.efsa.2026.9964 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EFSA Journal, 2026-03. Verfasst von EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) und 16 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Following an application from Anxiofit Ltd. pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of Hungary, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked for an opinion on the scientific substantiation of a health claim related to Anxiofit‐1 and reduction of subthreshold and mild anxiety. The food/constituent, Anxiofit‐1, an Echinacea angustifolia root extract, standardised for the content of echinacoside (at least 3%) and the profile of alkamides, is sufficiently characterised. The Panel considers that reduction of subthreshold and mild anxiety, risk factors for anxiety and depressive disorders, is a beneficial physiological effect. Two short‐term human intervention studies showed a selective effect of Anxiofit‐1 (80 mg/day for 7 days) on state anxiety and no effect on trait anxiety in subjects with subthreshold and mild anxiety. A randomised controlled trial (RCT) lasting 6 weeks showed no effect of Anxiofit‐1 at 40 or 80 mg/day on anxiety symptoms using a different psychometric tool. No evidence has been provided to establish that the short‐term, selective effect of Anxiofit‐1 on state anxiety observed in two RCTs can be sustained with continuous consumption of the food/constituent, or that a short‐term reduction of subthreshold anxiety (or state anxiety alone) reduces the risk of anxiety and depressive disorders in individuals with subthreshold anxiety. No human intervention studies investigating the effect of Anxiofit‐1 on the risk of anxiety and/or depressive disorders have been provided. The information submitted by the applicant does not provide evidence for a plausible mechanism by which Anxiofit‐1 could exert the claimed effect in vivo in humans. The Panel concludes that the scientific evidence is insufficient to establish a cause‐and‐effect relationship between the consumption of Anxiofit‐1 and the reduction of subthreshold and mild anxiety as risk factors for anxiety and depressive disorders.

Schlagwörter

Stichwörter der Autor:innen

Anxiofit‐1Echinacea angustifoliaanxietydepressionhealth claim

Zitieren

APA

EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck, D., Bohn, T., Cámara, M., Castenmiller, J., de Henauw, S., Hirsch-Ernst, K. I., Jos, A., Maciuk, A., Mangelsdorf, I., McNulty, B., Naska, A., Pentieva, K., Thies, F., Drenjančević, I., Craciun, I., & Siani, A. (2026). Anxiofit‐1 and reduction of subthreshold and mild anxiety: Evaluation of a health claim pursuant to article 14 of regulation (EC) No 1924/2006. EFSA Journal, 24(3). https://doi.org/10.2903/j.efsa.2026.9964

Vancouver

EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, Bohn T, Cámara M, Castenmiller J, de Henauw S, et al. Anxiofit‐1 and reduction of subthreshold and mild anxiety: Evaluation of a health claim pursuant to article 14 of regulation (EC) No 1924/2006. EFSA Journal. 2026;24(3). doi:10.2903/j.efsa.2026.9964

BibTeX
@article{EFSAPanelonNutritionNovelFoodsandFoodAllergensNDA2026,
  author = {EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) and Turck, Dominique and Bohn, Torsten and Cámara, Montaña and Castenmiller, Jacqueline and de Henauw, Stefaan and Hirsch-Ernst, Karen-Ildico and Jos, Angeles and Maciuk, Alexandre and Mangelsdorf, Inge and McNulty, Breige and Naska, Androniki and Pentieva, Kristina and Thies, Frank and Drenjančević, Ines and Craciun, Ionut and Siani, Alfonso},
  title = {Anxiofit‐1 and reduction of subthreshold and mild anxiety: Evaluation of a health claim pursuant to article 14 of regulation (EC) No 1924/2006},
  journal = {EFSA Journal},
  year = {2026},
  volume = {24},
  number = {3},
  doi = {10.2903/j.efsa.2026.9964}
}
Kostenlos starten →